279 results about "Cell sheet" patented technology

Provided is a method for screening myocardial therapeutic targets for ischemic heart failure by using single-cell sequencing, which method comprises the following steps: S1, sample preparation; S2, construction of a single-cell expression matrix; S3, cell quality control; S4, cell type annotation; S5, cell communication analysis; and S6, co-expression network analysis. The provided method for screening myocardial therapeutic targets for ischemic heart failure by using single-cell sequencing comprises performing single-cell sequencing on hearts of healthy mice and IHF mice, screening for cell types with significant differences in cardiac transcriptional profiles of the healthy mice and IHF mice, then exploring interaction characteristics of various types of cells in malignant fibrotic IHF hearts, revealing potential regulatory modules and pathways related to malignant myocardial fibrosis in single-cell expression data of IHF hearts, and performing screening to obtain Pdgfb and Tnfsf12 genes which can be used as therapeutic targets for treating myocardial fibrosis in ischemic heart failure.

A photovoltaic module and a photovoltaic system. The photovoltaic module includes a panel, a back plate, a cell sheet layer, and a first encapsulation adhesive film layer, wherein the back plate and the panel are stacked, the cell sheet layer is located between the panel and the back plate, the first encapsulation adhesive film layer is located between the cell sheet layer and the panel, a color layer is provided between the panel and the first encapsulation adhesive film layer, the color layer is a light-transmitting layer, and a relief structure is provided on the side of the panel facing away from the first encapsulation adhesive film layer. The relief structure can reduce the reflection of sunlight on the panel, thereby increasing the incident amount of sunlight and increasing the power generation of solar energy.

Methods for preparing a personalized cancer vaccine and a method to train a machine learning HLA-peptide presentation prediction model. Further wherein, a method of making a HLA class II tetramer or multimer comprising an epitope, the method comprising contacting a purified soluble HLA-DM loaded with a peptide epitope with a HLA class II tetramer or multimer, thereby forming a HLA class II tetramer or multimer loaded with the peptide epitope, is disclosed.

Provided are a method for inducing differentiation of pluripotent stem cells into CD34+ hematopoietic stem / progenitor cells and a culture medium composition thereof. Provided are a method for inducing differentiation of pluripotent stem cells into CD34+ hematopoietic stem / progenitor cells or NK cells and a culture medium composition thereof. The NK cells obtained using the provided culture method have high purity and good in vitro expansion effect; the yield of iNK cells is high, and a single iPSC can differentiate into approximately 2,000 NK cells; and the obtained iNK cells highly express CD16 (over 70%). As a result, the problem of low CD16 expression in iNK cells in the prior art, which requires genetic modification methods to solve, has been addressed.

The invention provides an anti-PD-1 antibody, a CAR-T cell, and a preparation method and application thereof. The anti-PD-1 antibody comprises LCDR-1-3 as shown in SEQ ID NO: 1-3 and HCDR-1-3 as shown in SEQ ID NO: 4-6, respectively. The CAR-T cell expresses a novel element for efficiently blocking the PD-1, and the element is a single-chain antibody for targeting the PD-1 in a cell membrane anchoring manner. And the chimeric antigen receptor and the cell membrane anchored anti-PD-1 scFv are connected by a 2A cleavage protein. The membrane anchor type anti-PD-1 scFv expressed by the CAR-T cell can almost completely block the expression of PD-1 on the surface of a T cell membrane, and further block a signal channel combined with PD-1 / PD-L1, so that the capability of T cell depletion caused by antagonism tumor of the CAR-T cell is enhanced, and the purpose of enhancing the anti-tumor effect of the CAR-T cell is achieved.

The invention provides a mother battery piece, a battery piece, a preparation method of the mother battery piece and a photovoltaic module. The battery piece comprises a first semiconductor substrate; the first doped semiconductor layer is arranged in the central region; the isolation groove is formed in the first isolation area and surrounds the central area; wherein the side surface comprises a first sub-surface, and the first sub-surface is connected with the groove wall of the isolation groove; the tunneling passivation contact structure is at least arranged on the second surface; the first passivation layer at least covers the first doped semiconductor layer, the isolation groove and the first sub-surface; wherein the first sub-surface and the second surface are both provided with a plurality of square tower footing structures, the difference between the side length of the largest square tower footing structure on the first sub-surface and the side length of the largest square tower footing structure on the second surface is a first numerical value, and the first numerical value is smaller than or equal to 15 microns. The battery efficiency can be improved, and the manufacturing cost can be reduced.

The invention provides an application of M1 as an affinity of human source PD-L1 and / or mouse source PD-L1, and relates to the technical field of biological medicine. The invention proves that M1 can be used as a PD-L1 affinity for human / mouse cross reaction, and has low nanomole affinity for two targets. In cell-based function detection, M1 has similar affinity with mPDL1 and hPD-L1 expressed on the surface of a cell, and signal transduction is inhibited through a PD-L1: PD1 axis at a low micromolar concentration. The M1 disclosed by the invention can be used as a non-antibody treatment method to damage a PD-L1: PD1 signal channel, and the M1 shows high tumor permeability compared with an antibody, and particularly has a remarkable advantage in tumors (such as pancreatic tumors) with high fiber hyperplasia; the M1 shows selective uptake in the tumor for expressing the PD-L1.

The invention relates to a method for rapidly preparing a cell scanning electron microscope sample through cell surface metal deposition. The method comprises immobilizing a cell sample with an immobilizing agent; incubating in a catalyst solution; placing in a metal deposition solution for cell metal deposition; the cell sample is obtained. The prepared cell sample can be directly used for scanning electron microscope imaging after being dried. According to the method, the micro-nano structure on the surface of the cell is directly mechanically enhanced in the solution through electroless metal deposition, the cell sample is endowed with electrical conductivity, additional chemical modification on the cell is not needed, gradient dehydration on the cell is not needed, and metal spraying treatment on the cell is not needed; and cell scanning electron microscope sample preparation and imaging can be conveniently and quickly carried out.

The invention relates to a welding method of a solar battery, which comprises the following steps of: providing a battery piece, and arranging a grid line on the side surface of the battery piece; forming an organic solderability preservative film on the side surface of the battery piece, and enabling the organic solderability preservative film to cover the outer surface of the grid line; completely removing the organic solderability preservative film covering the part, needing to be welded with the welding wire, of the grid line, so that the part, needing to be welded with the welding wire, of the grid line is exposed; wherein in the process of removing the organic solderability preservative film at the position, where the welding wire needs to be welded, on the grid line, the temperature of the position, except for the welding wire, on the battery piece is made to be smaller than or equal to 200 DEG C; and the exposed parts on the grid lines are welded and connected with the welding wires. On one hand, the organic solderability preservative film covers the outer surface of the grid line, an anti-oxidation effect can be achieved, and compared with a tin plating process, the production cost is low; and on the other hand, the temperature of the parts except for the welding wire on the battery piece is controlled to be less than or equal to 200 DEG C, and the temperature is relatively low, so that the influence on the performance of an amorphous silicon layer, a silicon substrate and the like of the battery piece can be avoided.

The invention relates to an antibody or an antigen fragment of a targeted human CD7 and application of the antibody or the antigen fragment. The antibody and the CD7-CAR based on the antibody fragment have extremely strong affinity with a CD7 antigen molecule, and a blocking molecule containing the antibody can almost completely block the expression of the CD7 molecule on the cell surface without influencing the normal amplification of T cells, so that the self-killing of the CD7-CAR-T cells can be effectively avoided. The CD7-CAR-T cell constructed on the basis of the single-domain antibody of the targeted human source CD7 has a strong killing effect on a target cell.

The present disclosure relates to methods of treating, preventing, or modulating diabetes in a patient in need thereof using a device for transplanting cells into a host body, specifically a method of treating diabetes in a patient in need thereof, comprising: implanting a device in the patient, wherein the device comprises: a porous scaffold comprising an immunologically compatible polymer mesh forming the walls of at least one chamber, an opening at either or both of a proximal end and a distal end of the chamber, at least one removable, non-porous plug configured to be positioned within the lumen of the at least one chamber, maintaining the device in the patient's body until the device is infiltrated with vascular and connective tissues; and infusing the chamber with cells, wherein at least some of the cells express insulin

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

An assay for autologous primary immune cells is described, in which individual blood cells can be functionally screened simultaneously for individual antigens of interest, such as T-cell epitopes, without the need for HLA haplotype-specific reagents. An oligonucleotide-labeled hash-tracking system, followed by deconvolution via single-cell sequencing, correlates antigen reactivity with individual T cells.

The invention discloses a method for bifluorescence quantitative detection of epithelial cells of a lacrimal gland organ and application. The method comprises the following steps: providing a mouse lacrimal gland organ; a recombinant adeno-associated virus combination is added to the organoid, the combination comprising: a first AAV vector comprising a promoter specifically driving the expression of alveolar epithelial cells and a first fluorescent protein coding sequence; the second AAV vector contains a promoter for specifically driving expression of myoepithelial cells and a second fluorescent protein coding sequence; according to the method, the two cells can be visually distinguished, and by calculating the fluorescence area or the number of the cells, the alveolar / muscular epithelial cell proportion is established as a damage index, so that high-throughput drug screening is realized.

This invention provides a cell population comprising mesenchymal cells capable of forming a cell sheet that can be spontaneously detached from a substrate. In such cell population comprising mesenchymal cells, the proportion of cells positive for CD324 is 70% or more and the proportion of mesenchymal cells positive for CD90 is 90% or more.

The present application relates to the technical field of biological medicine, and discloses a kind of living cell carrier and its preparation method and use.The method of the present application utilizes active ester compound containing alkynyl and reacts with living cells, and is connected to the surface of living cells, then combines with RAFT reaction chain transfer molecule, and then utilizes in-situ RAFT reaction to polymerize the polymerization monomer containing active group of required function on cell surface, so as to obtain the cell carrier with required function.

In the present invention, an antibody or antigen-binding fragment thereof that specifically binds to an extracellular region of the CD179b protein expressed on a cell surface and has the ability to be internalized into cells expressing the CD179b protein on the cell surface can be used as an intracellular drug delivery agent for delivering a drug into cells expressing the CD179b protein on the cell surface.

The invention discloses a preparation method and application of programmable DNA hydrogel for inhibiting breast cancer tumor activity. The DNA hydrogel is composed of an RCA long chain AL containing a multivalent AS411 aptamer sequence and an RCA long chain CL hybridized with a cholesterol single chain ss-chol. Through reasonable DNA programming sequence design, a three-dimensional DNA structure can be formed on the surface of the cell. The DNA hydrogel specifically targets cancer cells with high expression of nucleolin receptors through the synergistic effect of multivalent AS1411 and chol, and is weak in targeting to normal cells with low expression of nucleolin, so that toxic and side effects on the normal cells are effectively avoided. The DNA hydrogel has excellent programmability, hydrogel with high, medium and low pore densities can be simply prepared through flexible DNA sequence design, and the breast cancer resistance activity of the DNA hydrogel is in positive correlation with the pore density of the DNA hydrogel. In animal in-vivo experiments, the DNA hydrogel under three-dimensional and high pore density significantly inhibits breast cancer activity, and a new strategy is provided for tumor treatment.

The purpose of the present invention is to three-dimensionally culture osteoblasts produced with a direct conversion technique, and to provide a three-dimensional bone-like tissue composed of the osteoblasts and bone matrix. The present invention relates to, for example, a method for producing an osteoblast-containing three-dimensional cell mass, comprising: a first step for performing direct conversion from somatic cells of mammals into osteoblasts; a second step for subjecting cells having undergone the first step to high-density culture, and forming a cell sheet containing the osteoblasts; and a third step for obtaining an osteoblast-containing three-dimensional cell mass from the cell sheet obtained in the second step.

The present disclosure provides processes for genetically engineering T cells, such as primary CD4+ T cells and / or CD8+ T cells, for use in cell therapy that does not involve expanding the cells. In particular aspects, the provided processes successfully generate compositions of engineered T cells, such as containing populations of engineered T cells, that express a chimeric antigen receptor (CAR) within a shortened amount of time as compared to alternative engineering processes, such as processes that involve expanding the cells. In certain aspects, the provided processes successfully generate a composition of engineered T cells suitable for use in cell therapy within 4 days from when the process to stimulate or activate the cells is initiated. In some aspects, the resulting engineered cell compositions are composed of cell population that are less differentiated, less exhausted, and more potent than engineered T cell compositions generated by other means, such as by processes that involve expanding the cells. Also provided are compositions of T cells generated by the provided methods and their uses for treating subjects.

This provides machine learning techniques for predicting surface-presented peptides. [Solution] This disclosure provides a method for predicting surface-presented peptides using binding and surface-presentation properties. The method may include accessing a trained machine learning model configured to produce an output indicating the degree to which one or more expression levels and one or more peptide presentation metrics are related according to population-level relationships between expression and presentation. For each peptide in a set of peptides from a tissue sample, a score can be determined using the machine learning model and corresponding genomic and transcriptome data. The score predicts whether the corresponding peptide is a surface-presented peptide that binds to an MHC molecule and is presented on the cell surface.

This invention discloses a photovoltaic cell string manufacturing equipment, which includes a feeding mechanism, a ribbon feeding mechanism, a fixture loading and unloading mechanism, a welding mechanism, a coating and curing mechanism, and a cell string conveying mechanism. Through a traction mechanism and a robotic arm, multi-strand ribbons cut to the required process length and cell sheets are sequentially placed, allowing adjacent cells to be pre-welded into a cell string by the multi-strand ribbons on their front and back sides. In subsequent processes, adhesion points are coated on the front and back of the cell string, and curing thoroughly eliminates the risk of poor overlap. This eliminates the need for composite films and PAD points on the front and back of the cells, reducing shading on the photovoltaic cell surface and the use of silver paste, thus significantly reducing costs.

The present invention provides methods and compositions based on a non-naturally occurring nucleic acid construct encoding a fusion protein for quantifying secretion levels in an individual cell, which may comprise a protein sequence comprising a cytoplasmic domain, a transmembrane domain, and a vesicular domain, wherein the vesicular domain may comprise a sequence of protein marks, wherein upon expression of the fusion protein by a cell, the fusion protein localizes to the membrane of a secretory vesicle such that the protein mark is located in the lumen of the secretory vesicle, and wherein the protein mark binds to a cell-impermeable marker;whereby, after the secretion of the contents of the secretory vesicle, the protein tag is exposed to the cell-impermeable marker, the fusion protein is recycled back into the cell, and the individual cell is tagged with the marker in relation to the amount of secretion.

A continuous directed evolution platform in human B cell lines (CODE-HB) that recruits and repurposes the inherent B cell somatic hypermutation (SHM) mechanisms to rapidly evolve proteins is described. This approach uses stable, non-immunoglobulin loci within the genomes of human B cell lines for integration of a heterologous gene, such as a gene encoding an antibody or antibody fragment. A B-cell surface display platform for displaying fragment antigen binding domains (Fab) of antibodies is also described, which adapts the CODE-HB platform to rapidly evolve antibody fragments in a continuous manner. Plasmids and kits for carrying out these methods are also described.

Systems and methods for identifying cellular responses to candidate drugs, including treatment cycling, are described. These systems and methods utilize rapid response readout in combination with gentle removal and / or exchange of the analyte fluid. The systems and methods can be used, for example, in T-cell epitope mapping, T-cell diagnostics, and other cell-based high-throughput screening methods.

Disclosed herein are rare earth element (REE) sensors comprising an REE binding element and a fluorescent component, which can be expressed on a cell surface. Also disclosed are systems and methods of recovering rare earth elements from a sample, the method comprising exposing an aqueous solution comprising one or more rare earth elements. Also disclosed are methods of discovering new, useful REE binding elements.

Disclosed is a manufacturing method for a back-contact cell assembly. Cell sheets are wound multiple times around the outer periphery of a cylindrical body along a first winding direction to obtain a first cell preform; a solder ribbon is wound around the outer periphery of the first cell preform, and an included angle between the winding direction of the solder ribbon and the first winding direction is an acute angle; and the solder ribbon is divided into a plurality of sub-solder ribbons along a target position.

The invention is suitable for the field of photovoltaic technology, and provides a manufacturing method of a solar cell, the solar cell, a cell module, a method and a system. Providing a silicon substrate, wherein the silicon substrate comprises a front surface and a back surface which are opposite; performing laser processing on the silicon substrate to form a through hole, wherein a laser beam moving along a preset scanning path in the laser processing performs local area punching; the conductive paste is poured into the through hole, a curing process is carried out to form a conductor, and the conductor forms a conductive contact structure on the front face. The doped conductive layer is formed on the back face of the silicon substrate, the silicon substrate is punched to form the through hole, the conductive paste is poured into the through hole to form the conductor, and the conductive contact structure is formed on the front face of the silicon substrate; the front surfaces of the battery pieces are provided with the electrode structures, so that when the battery pieces are overlapped, two adjacent battery pieces can be directly overlapped to be electrically connected, a welding strip is omitted, and the series welding process among a plurality of battery pieces is simplified.